Skip to main content
SpringerLink
Log in

The Pharmaceutical Medicine Year That Was

A View from San Diego, California, at the End of 2007

  • Commentary
  • Published:
International Journal of Pharmaceutical Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 1 The use of trade names is for product identification purposes only and does not imply endorsement.

  2. 2 In August 2007, the FDA did mandate a class-label change, warning of an association with cardiac failure, for all thiazolidinediones. GSK had submitted a supplemental labelling change request for this in the autumn of 2006, as a separate matter, and no action had been taken by the FDA prior to the events associated with the meta-analysis.

  3. 3 The author discloses a financially uncompensated association with a company that is specifically designed to facilitate this process.

References

  1. Fox AW. The US Food and Drug Administration and emergency contraception. Int J Pharm Med 2005; 19 (3): 139–40

    Article  Google Scholar 

  2. Fox AW. Report on drug safety and the US FDA by the Institute of Medicine. Int J Pharm Med 2006; 20: 289–91

    Article  Google Scholar 

  3. Nissen SE, Wolski K. Effcet of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–71

    Article  PubMed  CAS  Google Scholar 

  4. Pringle E. Partners in crime: the FDA, GlaxoSmithKline and the Avandia disaster. 2007 Jun 4 [online]. Available from URL: http://www.counterpunch.org/pringle06042007. html [Accessed 2007 Oct 23]

    Google Scholar 

  5. Pasty BM, Furberg C. Rosiglitazone and cardiovascular risk [editorial]. N Engl J Med 2007; 356: 2522–4

    Article  Google Scholar 

  6. Sykes R. Being a modern pharmaceutical company. BMJ 1998; 317: 1172–80

    Article  PubMed  CAS  Google Scholar 

  7. US Food and Drug Administration. FDA announces results of investigation into illegal promotion of OxyContin by the Purdue Frederick Company, Inc.: company misrepresented prescription pain reliever to health care professionals [press release]. May 10, dy2007 [online]. Available from URL: http://www. fda.gov/bbs/topics/NEWS/2007/NEW01632.html [Accessed 2007 Oct 23]

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. EBD Group, 2032 Corte del Nogal #120, Carlsbad, CA, 92009, USA

    Anthony W. Fox (Consulting Editor, International Journal of Pharmaceutical Medicine)

Authors
  1. Anthony W. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fox, A.W. The Pharmaceutical Medicine Year That Was. Int J Pharm Med 21, 387–389 (2007). https://doi.org/10.2165/00124363-200721060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00124363-200721060-00002

Keywords

Search

Navigation